Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02887976 · ClinicalTrials.gov registry record · Phase 3
Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201
A Phase 3 study of Prostate Cancer, sponsored by GU Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
- 3
- Study locations
NCT02887976: Completed Phase 3 study of Prostate Cancer, sponsored by GU Research Network.
NCT02887976 is a Phase 3 study of Prostate Cancer that has completed, run by GU Research Network. The registered enrollment target is 2 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02887976, a Phase 3 study of Prostate Cancer, has completed, sponsored by GU Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
- 3
- Study locations
Study Summary
An Open-label extension (OLE), expanded access study, to assess long-term safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in patients who completed study number CHL-AA-201.
Conditions Studied
Interventions
- DRUG Methylprednisolone
- DRUG SoluMatrix™ Abiraterone Acetate
Study Locations (3)
Nebraska
- GU Research Network/Urology PC - Lincoln
- GU Research Network/Urology Cancer Center - Omaha
Kansas
- GU Research Network/Wichita Urology Group - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-10-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02887976
The ClinicalTrials.gov registry entry for NCT02887976 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (100% lower). The listed sponsor is GU Research Network, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Methylprednisolone is the first listed.
NCT02887976 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Nebraska, Kansas.
Frequently Asked Questions
What is clinical trial NCT02887976 about?
NCT02887976 is a clinical study titled "Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201". An Open-label extension (OLE), expanded access study, to assess long-term safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in patients who completed study number CHL-AA-201.
What is the current status of trial NCT02887976?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2016-09. Estimated completion is 2017-10-06.
What conditions does trial NCT02887976 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02887976?
The interventions under investigation include: Methylprednisolone (DRUG), SoluMatrix™ Abiraterone Acetate (DRUG).
Who is sponsoring clinical trial NCT02887976?
This trial is sponsored by GU Research Network, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02887976 being conducted?
This trial has 3 study locations across Kansas, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.